217798-39-5
217798-39-5 structure
- Name: Ethaselen
- Chemical Name: 2,2'-(1,2-Ethanediyl)bis(1,2-benzoselenazol-3(2H)-one)
- CAS Number: 217798-39-5
- Molecular Formula: C16H12N2O2Se2
- Molecular Weight: 422.199
- Catalog: Research Areas Cancer
- Create Date: 2018-07-17 21:26:13
- Modify Date: 2024-01-02 09:50:58
-
Ethaselen (BBSKE) is an orally active, selective thioredoxin reductase (TrxR) inhibitor with IC50s of 0.5 and 0.35 μM for the wild-type human TrxR1 and rat TrxR1, respectively. Ethaselen specifically binds to the unique selenocysteine-cysteine redox pair in the C-terminal active site of mammalian TrxR1. Ethaselen, an organoselenium compound, is a potent antitumor candidate that exerts potent inhibition on non-small cell lung cancer (NSCLC) by targeting TrxR[1][2].
| Name | 2,2'-(1,2-Ethanediyl)bis(1,2-benzoselenazol-3(2H)-one) |
|---|---|
| Synonyms |
2,2'-(1,2-Ethanediyl)bis(1,2-benzoselenazol-3(2H)-one)
1,2-Benzisoselenazol-3(2H)-one, 2,2'-(1,2-ethanediyl)bis- |
| Description | Ethaselen (BBSKE) is an orally active, selective thioredoxin reductase (TrxR) inhibitor with IC50s of 0.5 and 0.35 μM for the wild-type human TrxR1 and rat TrxR1, respectively. Ethaselen specifically binds to the unique selenocysteine-cysteine redox pair in the C-terminal active site of mammalian TrxR1. Ethaselen, an organoselenium compound, is a potent antitumor candidate that exerts potent inhibition on non-small cell lung cancer (NSCLC) by targeting TrxR[1][2]. |
|---|---|
| Related Catalog | |
| Target |
TrxR[1] |
| In Vitro | Ethaselen (2.5-10 μM; 12, 24 hours) suppresses A549 cell viability in a both concentration- and time-dependent manner. H1666, which has considerably lower TrxR1 expression level, is less susceptible to 24 h treatment with Ethaselen[1]. Ethaselen inhibits the intracellular TrxR1 activity in a concentration- and time-dependent manner, with IC50 values of 4.2 and 2 μM for 12- and 24-h treatments, respectively[1]. Ethaselen (2.5-10 μM; 12, 24 hours) has no effect on the protein amounts of TrxR1 and Trx. The mRNA level of TrxR1 does not show significant alteration in Ethaselen-treated A549 cells[1]. Ethaselen (2.5-50 μM; 1-24 hours) causes intracellular Trx oxidation in A549 cells[1]. Ethaselen (5-10 μM; 12, 24 hours) causes a clear concentration-dependent increase in ROS levels in A549 cells[1]. The inhibition constants for Ethaselen binding to free enzyme (Ki) and the enzyme-substrate complex (Kis) were determined to be 0.022 and 0.087 μM, respectively. Ethaselen also inhibits mammalian TrxR1 in a time-dependent manner possibly by forming a covalent Se-S bond with Cys497 of Trx[1]. Cell Viability Assay[1] Cell Line: A549 cell Concentration: 2.5, 5, 7.5, 10 μM Incubation Time: 12, 24 hours Result: Suppressed A549 cell viability in a both concentration- and time-dependent manner. |
| In Vivo | Ethaselen (BBSKE; 36-108 mg/kg/day; PO; for 10 days) shows increased inhibition of tumor growth in a dose-independent manner[2]. Animal Model: Five-week-old female BALB/c nude mice with A549 cell[2] Dosage: 36, 72, 108 mg/kg Administration: PO; daily; for 10 days Result: Showed increased inhibition of tumor growth, and the inhibition levels increased with the dose. The TrxR activity levels of the high dose group (108 mg/kg) decreased more than the middle dose group (72 mg/kg) and low dose group (36 mg/kg). |
| References |
| Boiling Point | 580.5±60.0 °C at 760 mmHg |
|---|---|
| Molecular Formula | C16H12N2O2Se2 |
| Molecular Weight | 422.199 |
| Flash Point | 304.9±32.9 °C |
| Exact Mass | 423.922913 |
| Vapour Pressure | 0.0±1.6 mmHg at 25°C |